Theravance Biopharma, Inc.
TBPH
$16.48
-$0.04-0.24%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 114.54M | 105.90M | 29.34M | 13.03M | -58.33M |
| Total Depreciation and Amortization | 5.70M | 5.64M | 5.61M | 5.76M | 5.97M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 4.18M | 6.53M | 2.01M | 2.95M | 16.72M |
| Change in Net Operating Assets | 144.36M | 120.47M | 206.74M | 223.28M | 68.17M |
| Cash from Operations | 268.78M | 238.54M | 243.70M | 245.02M | 32.53M |
| Capital Expenditure | -42.00K | -42.00K | -224.00K | -239.00K | -241.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -83.28M | -105.24M | -89.96M | -7.10M | 26.13M |
| Cash from Investing | -83.32M | -105.28M | -90.19M | -7.34M | 25.89M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1.01M | 786.00K | 461.00K | 208.00K | 627.00K |
| Repurchase of Common Stock | -8.98M | -4.03M | -2.58M | -2.30M | -2.26M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -7.97M | -3.25M | -2.12M | -2.09M | -1.64M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 177.49M | 130.01M | 151.40M | 235.58M | 56.78M |